OncoMatch/Clinical Trials/NCT07283822
Amping up With PemJAK
Is NCT07283822 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Pembrolizumab for non-hodgkin lymphoma.
Treatment: Ruxolitinib · Pembrolizumab — The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Allowed: CD30 expression >10%
Other PTCL subtypes that express CD30 (>10%), must have received prior CD30-directed therapy.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: CD30-directed therapy — systemic ALCL
Patients with systemic ALCL must have received prior CD30-directed therapy.
Must have received: CD30-directed therapy — PTCL subtypes with CD30 expression >10%
Other PTCL subtypes that express CD30 (>10%), must have received prior CD30-directed therapy.
Cannot have received: chemotherapy or immunotherapy
Exception: must not have received within 2 weeks prior to entering the study
Patients must not have had chemotherapy or immunotherapy within 2 weeks prior to entering the study
Lab requirements
Blood counts
ANC ≥ 1000/μL (not growth factor independent); Platelets ≥ 70,000/μL (or ≥50,000/mm3 if known bone marrow involvement with dose modifications allowed); Baseline hemoglobin level ≥ 8 g/dL (irrespective of bone marrow involvement)
Kidney function
Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault formula
Liver function
Bilirubin ≤ 2 x ULN; AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN
Organ function as assessed by laboratory testing and ECOG performance status 0-2 and or a Karnofsky performance score of equal or greater to 50
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Columbia University Irving Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07283822 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy or immunotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 95 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages